
|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| SEC Form 3 |  |  |  |  |  |  |
| **FORM 3** | **UNITED STATES SECURITIES AND EXCHANGE** |  |  |  |  |  |
|  | **COMMISSION** |  |  | |  |  |
|  |  |  | |  |  |
|  |  | OMB APPROVAL | | |  |
|  | Washington, D.C. 20549 |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  | OMB Number: | 3235- |  |  |
|  |  |  |  |  |
|  |  |  | 0104 |  |  |
|  | **INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF** |  |  |  |  |
|  |  | Estimated average burden | | |  |
|  | **SECURITIES** |  | response: | 0.5 |  |  |
|  |  |  | hours per |  |  |  |



Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

or Section 30(h) of the Investment Company Act of 1940



|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 1. Name and Address of Reporting Person\* | | | 2. Date of Event |  |
|  | [Autor Deborah M.](http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001884671) | | Requiring Statement |  |
|  | (Month/Day/Year) |  |
|  |  |  | 07/29/2022 |  |

(Last) (First) (Middle)

C/O AMNEAL

PHARMACEUTICALS, INC.

400 CROSSING BOULEVARD

|  |  |
| --- | --- |
| (Street) |  |
| BRIDGEWATER NJ | 08807 |

3. Issuer Name **and** Ticker or Trading Symbol

[Amneal Pharmaceuticals, Inc.](http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001723128) [ AMRX ]

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 4. Relationship of Reporting Person(s) to | | 5. | If Amendment, Date of Original | |  |
| Issuer |  | Filed (Month/Day/Year) | | |  |
| (Check all applicable) |  |  |  |  |  |
| X Director | 10% Owner |  |  |  |  |
| 6. | Individual or Joint/Group Filing | |  |
| Officer (give | Other (specify |  |
| (Check Applicable Line) | | |  |
| title below) | below) |  | X | Form filed by One Reporting |  |
|  |  |  |  |
|  |  |  |  | Person |  |

Form filed by More than One

Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Beneficially Owned**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **1. Title of Security (Instr. 4)** | **2. Amount of Securities** | **3. Ownership** | **4. Nature of Indirect Beneficial** | |
|  |  | **Beneficially Owned (Instr.** | **Form: Direct** | **Ownership (Instr. 5)** | |
|  |  | **4)** | **(D) or Indirect** |  |  |
|  |  |  | **(I) (Instr. 5)** |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |

**Table II - Derivative Securities Beneficially Owned**

**(e.g., puts, calls, warrants, options, convertible securities)**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **1. Title of Derivative Security (Instr. 4)** | **2. Date Exercisable and** | | **3. Title and Amount of Securities** | | **4.** | **5.** | **6. Nature of** |  |
|  | **Expiration Date** | | **Underlying Derivative Security** | | **Conversion** | **Ownership** | **Indirect Beneficial** |  |
|  | **(Month/Day/Year)** | | **(Instr. 4)** |  | **or Exercise** | **Form:** | **Ownership (Instr.** |  |
|  |  |  |  |  | **Price of** | **Direct (D)** | **5)** |  |
|  |  |  |  | **Amount** |  |
|  |  |  |  | **Derivative** | **or Indirect** |  |  |
|  |  |  |  | **or** | **Security** | **(I) (Instr. 5)** |  |  |
|  |  |  |  | **Number** |  |  |  |  |
|  | **Date** | **Expiration** |  | **of** |  |  |  |  |
|  | **Exercisable** | **Date** | **Title** | **Shares** |  |  |  |  |

**Explanation of Responses:**

**Remarks:**

Exhibit List: Exhibit 24 - Power of Attorney.

**No securities are beneficially owned.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Jason B. Daly, as | | | 08/02/2022 |  |
|  | Attorney-in-Fact | |  |  |
|  |  |  |
|  |  |  | |  |  |
|  | \*\* Signature of Reporting | | | Date |  |
|  | Person | | |  |
|  |  |  |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | | | |  |  |
| \* If the form is filed by more than one reporting person, *see* Instruction 5 (b)(v). | | | |  |  |

* Intentional misstatements or omissions of facts constitute Federal Criminal Violations *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

Exhibit 24

POWER OF ATTORNEY

Know all by these presents, that the undersigned, does hereby make, constitute and appoint Jason B. Daly, the current Chief Legal Officer of Amneal Pharmaceuticals, Inc., a Delaware corporation (the "Company") as a true and lawful attorney-in-fact of the undersigned with full powers of substitution and revocation, for and in the name, place and stead of the undersigned (in the undersigned's individual capacity) to:

1. prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC;
2. execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and, 'or director of the Company, and/or 10% holder of the Company's capital stock, Forms 3, 4, and 5 and any amendments thereto in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
3. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and
4. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 25th day of July 2022.

/s/ Deborah M. Autor

By: Deborah M. Autor